Key facts
- Portrai’s last known valuation is $14.9M (Mar 2023).
- It has raised $14.5M; the latest was Early Stage VC ($9.9M) in Dec 2025.
- Notable investors include Kakao Ventures, BonAngels Venture Partners, Schmidt (South Korea), Stic Alternative, Amgen — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Portrai
- ·The full record, as it builds
Funding rounds
No funding rounds for Portrai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Portrai
Developer of a spatial transcriptomics platform intended to improve biopsy quality by applying artificial intelligence. The company's platform discovers therapeutic targets and explores potential disease indications with high spatial resolution, translates spatial insights into pathophysiology and drug distribution, and develops and validates spatial biomarkers and companion diagnostics, enabling healthcare institutions to enhance precision medicine strategies and therapeutic efficacy.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 15
- Website
- portrai.io/
- Ownership
- Privately Held (backing)
Portrai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Portrai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Portrai in its N-PORT filings yet. We sweep new filings monthly.